Literature DB >> 14667095

Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus.

S Morelli1, M L Bernardo, F Viganego, A Sgreccia, P De Marzio, F Conti, R Priori, G Valesini.   

Abstract

The aim of the study was to assess the relationship between ischemic cerebrovascular accidents (ICVAs), that is, transient ischemic attack (TIA) or stroke, and left-sided heart valve abnormalities (LHVAs) in patients with systemic lupus erythematosus (SLE). In total, 71 consecutive SLE patients were studied. At baseline, history, clinical and laboratory evaluations, as well as trans-thoracic echocardiography (TTE) were performed. From the original population, so patients were followed up for a mean time of 5.80 +/- 1.53 years. After a mean period of 5.39 +/- 1.42 years; 40 patients underwent a repeat TTE. Previous ICVA history was present at baseline in 16 patients (22.5%). Of these, 13 (81.2%) had evidence of LHVAs on TTE. Previous ICVAs were significantly associated to diagnosis of secondary anti-phospholipid syndrome (SAPS), positivity for anti-cardiolipin antibodies (aCl), and LHVAs. Multivariate analysis confirmed the correlation between previous ICVAs and LHVAs. LHVAs were not more commonly observed in patients with SAPS compared to patients without SAPS. At the end of follow-up, irrespective of any differences in antithrombotic treatment, ICVAs had occurred in 13 patients. During follow-up, ICVAs had recurred in seven patients, while a first event TIA occurred in one patient. Multivariate analysis confirmed the relationship between ICVAs and LHVAs, and a trend towards a positive correlation of the former with SAPS. This study demonstrates that LHVAs represent a compelling risk factor for the development of ICVAs in SLE patients. Conversely, SAPS and aCl positivity, although associated with ICVAs, did not clearly correlate with LHVAs in our study. These results provide insight on the pathogenesis of ICVAs and may give clues on the potential efficacy of preventive/therapeutic strategies in different SLE subpopulations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667095     DOI: 10.1191/0961203303lu468oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

1.  Libman-Sacks endocarditis and embolic cerebrovascular disease.

Authors:  Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Rex E Jung; Ernest R Greene; Charles M Gasparovic; Reyaad A Hayek; Gerald A Charlton; Kendall Crookston
Journal:  JACC Cardiovasc Imaging       Date:  2013-09

2.  Cardiac manifestations of Han Chinese patients with systemic lupus erythematosus: a retrospective study.

Authors:  Ertao Jia; Hongling Geng; Qingping Liu; Yuya Xiao; Yanying Zhang; Jingjing Xie; Luhe Zhang; Xia Qiu; Li Zhong; Min Xiao; Jianyong Zhang
Journal:  Ir J Med Sci       Date:  2018-11-20       Impact factor: 1.568

3.  Libman-Sacks Endocarditis: Detection, Characterization, and Clinical Correlates by Three-Dimensional Transesophageal Echocardiography.

Authors:  Carlos A Roldan; Kirsten Tolstrup; Leonardo Macias; Clifford R Qualls; Diana Maynard; Gerald Charlton; Wilmer L Sibbitt
Journal:  J Am Soc Echocardiogr       Date:  2015-03-22       Impact factor: 5.251

4.  Association of annular calcification and aortic valve sclerosis with brain findings on magnetic resonance imaging in community dwelling older adults: the cardiovascular health study.

Authors:  Carlos J Rodriguez; Traci M Bartz; W T Longstreth; Jorge R Kizer; Eddy Barasch; Donald M Lloyd-Jones; John S Gottdiener
Journal:  J Am Coll Cardiol       Date:  2011-05-24       Impact factor: 24.094

Review 5.  Valvular heart disease in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Olivier Huttin; Shirine Mohamed; Pierre-Yves Marie; Christine Selton-Suty; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

6.  Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study.

Authors:  Kumar Rajamani; Seemant Chaturvedi; Zhezhen Jin; Shunichi Homma; Robin L Brey; Barbara C Tilley; Ralph L Sacco; J L P Thompson; J P Mohr; Steven R Levine
Journal:  Stroke       Date:  2009-06-04       Impact factor: 7.914

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.